Nivolumab has been used to effectively manage advanced cancers with abundant expression of ligands of PD-1 on their tumor cell surfaces, such as relapsed Hodgkin lymphoma (HL), non-small-cell lung cancer, and metastatic melanoma, because of this distinct mechanism of action [4–6]. This evidence concerns the gene PDCD1 and cancer.